March 8, 2019: A phase I Big Ten Cancer Research Consortium study for adult patients with relapsed or refractory Classical Hodgkin lymphoma is open for accrual at Masonic Cancer Center, University of Minnesota; the University of Illinois Cancer Center; the University of Wisconsin Carbone Cancer Center; and the University of Iowa Holden Comprehensive Cancer Center.… Read More
The post Big Ten CRC study to help determine maximum dosage of ruxolitinib when combined with nivolumab in Hodgkin lymphoma patients appeared first on Big Ten Cancer Research Consortium.
Read the full article at: https://www.bigtencrc.org/big-ten-crc-study-to-help-determine-maximum-dosage-of-ruxolitinib-when-combined-with-nivolumab-in-hodgkin-lymphoma-patients/